Imaging prostate cancer: An update on positron emission tomography and magnetic resonance imaging

被引：37

作者：

Bouchelouche K. ^{[1
]}

Turkbey B. ^{[2
]}

Choyke P. ^{[2
]}

Capala J. ^{[3
]}

机构：

[1] PET and Cyclotron Unit, University of Copenhagen, Rigshospitalet, Copenhagen 2100

[2] Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD

[3] Molecular Targeting Section, National Cancer Institute, National Institutes of Health, Bethesda, MD

来源：

Current Urology Reports | 2010年 / 11卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Diffusion-weighted MRI; Dynamic contrast-enhanced MRI; Imaging; Magnetic resonance imaging; Magnetic resonance spectroscopy; MRI; MRS; PET; PET/CT; Positron emission tomography; Prostate cancer;

D O I：

10.1007/s11934-010-0105-9

中图分类号：

学科分类号：

摘要：

Prostate cancer is a common cancer in men and continues to be a major health problem. Imaging plays an essential role in the clinical management of patients. An important goal for prostate cancer imaging is more accurate disease characterization through the synthesis of anatomic, functional, and molecular imaging information. Developments in imaging technologies, specifically magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT), have improved the detection rate of prostate cancer. MRI has improved lesion detection and local staging. Furthermore, MRI allows functional assessment with techniques such as diffusion-weighted MRI, MR spectroscopy, and dynamic contrast-enhanced MRI. The most common PET radiotracer, 18F-fluorodeoxyglucose, is not very useful in prostate cancer. However, in recent years other PET tracers have improved the accuracy of PET/CT imaging of prostate cancer. Among these, choline (labeled with 18F or 11C), 11C-acetate, and 18F-fluoride have demonstrated promising results, and other new radiopharmaceuticals are currently under evaluation in preclinical and clinical studies. © 2010 Springer Science+Business Media, LLC.

引用

页码：180 / 190

页数：10

共 62 条

[1]

Damber J.-E., Aus G., Prostate cancer, The Lancet, 371, 9625, pp. 1710-1721, (2008)

[2]

Lassi K., Dawson N.A., Emerging therapies in castrate-resistant prostate cancer, Curr Opin Oncol, 21, pp. 260-265, (2009)

[3]

Bouchelouche K., Capala J., Oehr P., Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer, Curr Opin Oncol, 21, pp. 469-474, (2009)

[4]

Bouchelouche K., Capala J., Image and treat': An individualized approach to urological tumors, Curr Opin Oncol, (2010)

[5]

Kelloff G.J., Choyke P., Coffey D.S., Challenges in clinical prostate cancer: Role of imaging, AJR Am J Roentgenol, 192, pp. 1455-1470, (2009)

[6]

Turkbey B., Albert P.S., Kurdziel K., Choyke P.L., Imaging localized prostate cancer: Current approaches and new developments, AJR Am J Roentgenol, 192, pp. 1471-1480, (2009)

[7]

Apolo A.B., Pandit-Taskar N., Morris M.J., Novel tracers and their development for the imaging of metastatic prostate cancer, J Nucl Med, 49, pp. 2031-2041, (2008)

[8]

Turkbey B., Pinto P.A., Choyke P.L., Imaging techniques for prostate cancer: Implications for focal therapy, Nat Rev Urol, 6, pp. 191-203, (2009)

[9]

Bouchelouche K., Oehr P., Positron emission tomography and positron emission tomography/ computerized tomography of urological malignancies: An update review, Journal of Urology, 179, 1, pp. 34-45, (2008)

[10]

Jana S., Blaufox M.D., Nuclear medicine studies of the prostate, testes, and bladder, Seminars in Nuclear Medicine, 36, 1, pp. 51-72, (2006)

← 1 2 3 4 5 6 7 →